VITA 34 International AG: Diabetes Research Institute received IND approval for a clinical study in newly manifested Type 1 Diabetes children using autologous 'Nabelschnurblut VITA34'

Leipzig, (PresseBox) - VITA 34 International AG (ISIN DE000A0BL849), the parent company of the leading private umbilical cord blood bank in the German-speaking countries VITA 34, received IND approval of its autologous Cord Blood for a clinical study in children with Type 1 Diabetes. The study will be performed by the Diabetes Research Institute of the Klinik und Poliklinik für Kinder- und Jugendmedizin of the Technical University Munich. A corresponding approval was granted by The Paul-Ehrlich-Institute, a high federal agency in Germany. The aim of the study is to investigate the safety and potential benefit of transfusing autologous Cord Blood in children who have newly manifested Type 1 Diabetes. The study is designed to last 24 months and will be controlled by a reference group. The risk of Type 1 Diabetes in Germany is about 1 in 600 by the age of fourteen. A similar pilot study in the USA shows promising results with regard to the disturbed immune balance, insulin requirements, and the quality of metabolic control.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.